Octreotide
Also known as: Longastatina, Octreotide, Octreotide acetate, Sandostatin, Sandostatin LAR, SMS 201-995
Source Octreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Octreotide is a cyclic octapeptide that mimics somatostatin, used to control hormone‑excess states such as acromegaly, carcinoid syndrome, and vasoactive intestinal peptide tumors.
Mechanism of Action
high‑affinity agonist at somatostatin receptors (mainly SSTR2 and SSTR5) inhibiting hormone secretion and cell proliferation
Routes of Administration
Goals & Uses
- Esophageal variceal bleedingGastroenterologyHigh
- Acromegaly managementEndocrinologyHigh
- Neuroendocrine tumor (NET) antiproliferative therapyOncologyHigh
- Prevent bleeding from esophageal varicesGastroenterologyModerate
- Carcinoid syndrome symptom controlOncology/GastroenterologyHigh
- Mitigate carcinoid syndrome symptomsOncologyHigh
- Treat vasoactive intestinal peptide tumors (VIPoma)GastroenterologyModerate
- Control acromegalyEndocrineHigh
- Dumping syndrome managementGastroenterologyModerate
- VIPoma managementOncology / NeuroendocrineHigh
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to octreotide or any excipientsAllergyHigh
- Severe biliary obstruction or active gallbladder diseaseGastrointestinalModerate
- Hypersensitivity to octreotide or excipientsAllergyHigh
- Pregnancy (relative)ReproductiveModerate
Adverse Effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)GastrointestinalCommon
- Cholelithiasis / gallstonesGastrointestinalCommon
- Hyperglycemia or hypoglycemiaMetabolic/EndocrineCommon
- Injection site reactionsLocalCommon
- Bradycardia / cardiac conduction abnormalitiesCardiovascularUncommon
- Nausea and abdominal painGastrointestinalCommon
- Gallstone formationHepatobiliaryCommon
- Hypoglycemia or hyperglycemiaMetabolicUncommon
- HypothyroidismEndocrineUncommon
Drug Interactions
- QT-prolonging drugs (e.g., amiodarone, sotalol)Moderate
- Insulin / Oral antidiabeticsModerate
- Beta-blockersModerate
- CyclosporineModerate
- BromocriptineLow
- Insulin or oral hypoglycemicsModerate
- Other somatostatin analogsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairment (cirrhosis)Organ ImpairmentRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- ElderlyAgeRelative
- Pregnant womenReproductiveRelative
- Diabetic PatientsMetabolicRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Acromegaly, Carcinoid syndrome, VIPoma, Bleeding esophageal varices
- United StatesApprovedApproved: Acromegaly, Carcinoid syndrome diarrhea, VIPomaShort‑acting and long‑acting depot formulations available
- United KingdomApprovedApproved: Acromegaly, Carcinoid syndrome, VIPoma
FDA‑approved (1988) for acromegaly and carcinoid syndrome; also approved in EU and UK for similar indications. Long‑acting depot formulation (Octreotide LAR) approved for chronic use.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Octreotide?
Octreotide is a cyclic octapeptide that mimics somatostatin, used to control hormone‑excess states such as acromegaly, carcinoid syndrome, and vasoactive intestinal peptide tumors.
What is Octreotide used for?
Octreotide is educationally associated with: Esophageal variceal bleeding, Acromegaly management, Neuroendocrine tumor (NET) antiproliferative therapy, Prevent bleeding from esophageal varices, Carcinoid syndrome symptom control, Mitigate carcinoid syndrome symptoms, Treat vasoactive intestinal peptide tumors (VIPoma), Control acromegaly, Dumping syndrome management, VIPoma management. Educational only — not medical advice.
How is Octreotide administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Octreotide?
Reported adverse effects include: Gastrointestinal disturbances (nausea, diarrhea, abdominal pain), Cholelithiasis / gallstones, Hyperglycemia or hypoglycemia, Injection site reactions, Bradycardia / cardiac conduction abnormalities, Nausea and abdominal pain, Gallstone formation, Hypoglycemia or hyperglycemia, Hypothyroidism. This list is not exhaustive — consult a qualified clinician.
Who should avoid Octreotide?
Recorded contraindications: Pregnancy, Hypersensitivity to octreotide or any excipients, Severe biliary obstruction or active gallbladder disease, Hypersensitivity to octreotide or excipients, Pregnancy (relative). Consult a qualified clinician before use.